FIT screening

Dikkedarmkanker, ook wel colorectaal carcinoom, is een veelvoorkomende ziekte onder voornamelijk ouderen. Het detecteren van dikke darmkanker in een vroeg stadium kan de overlevingskans van een patiënt aanzienlijk vergroten. Door gebruik te maken van een fecale immunochemische test (FIT) worden kleine hoeveelheden bloed (met behulp van antilichamen voor humaan hemoglobine) opgespoord in ontlastingsmonsters.

Sysmex biedt FIT-tests aan voor twee hoofdgroepen: grootschalig tests voor nationale of regionale bevolkingsonderzoeken, en symptomatische tests die hoofdzakelijk plaatsvinden in ziekenhuizen of klinische omgevingen. Lees hier meer over op onze FIT screening microsite

Sysmex Establishes Subsidiary in Egypt and Begins Conducting Direct Sales and Services

Datum: 2018-07-10 Tags: Persbericht

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has established a new subsidiary in Egypt and will begin conducting direct sales and services with the aim of expanding its business in the Middle East.

In recent years, Egypt has been setting up healthcare infrastructure in line with the country’s economic expansion and population growth. The healthcare market is expected to expand further, and demand is growing for sophisticated testing and healthcare services.

To date, Sysmex has developed its business in Egypt via local distributors, centered on the hematology field, through its subsidiary in Dubai (Sysmex Middle East FZ-LLC) which manages business operations in the Middle East (including Egypt) and Northeast Africa.

To further reinforce its business foundation in anticipation of growth in Egypt, where the market is growing at a rapid pace even compared with other parts of the Middle East, Sysmex has decided to establish a new subsidiary there and transition from a system of conducting sales and providing services through local distributors to a direct sales and service structure.

Going forward, we plan to begin providing products and services in the urinalysis and hemostasis fields, the life science field and to address three of the most leading infectious diseases (HIV/AIDS, tuberculosis and malaria), expanding our existing product portfolio centered on the hematology field. At the same time, by communicating directly with customers we aim to provide solutions in response to diverse needs and regional characteristics. Furthermore, by expanding our scientific awareness activities and thereby leveraging our strength in this area, we aim to further enhance customer satisfaction and expand our business.

Going forward, Sysmex will continue to augment its sales and service structure, provide distinctive services and support, and contribute to the advancement of healthcare.

Overview of the New Subsidiary

  • Name: Sysmex Egypt LLC
  • Location: Cairo, Egypt
  • Capital: 10,000,000 EGP (Egyptian pounds)
  • Employees: 21 (planned for fiscal 2018)
  • Line of business: Sales and maintenance services for in vitro diagnostic instruments, reagents and laboratory information systems

*Information contained in the press release is current as of the date of the announcement, but may be subject to change without prior notice.

Terug naar lijst
Enjoy our Media Centre
  • All
  • Documents
  • Podcast
  • Beelden
  • Video's
See our library of smears
Learn more about our concept
Growing your knowledge Visit our Academy
Sysmex XN – TAILORING YOUR HAEMATOLOGY See the scalability of XN
See our library of smears
Growing your knowledge Visit our Academy
Sysmex XN – TAILORING YOUR HAEMATOLOGY See the scalability of XN